Beta Interferon - Articles

Sort by: Relevance Newest Most Comments

Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis by stuart Patient Expert

Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis PubMed - 2008 Jun 4. [Epub ahead of print] Birnbaum G, Cree B, Altafullah I, Zinser M, Re ... Read on »

Merck Serono Launches New Formulation Of Interferon Beta-1a by stuart Patient Expert

Medical News Today Article Date: 03 Mar 2008 - 12:00 PST Merck Serono, a division of Merck KGaA, has announced that Rebif® New Formulation (interferon beta-1a) will be available in the UK. In a recent two-year (96 week) Phase IIIb study, 260 patients with relapsing remitting multiple sclerosis treated with the new formulatio ... Read on »

Coping strategy and anxiety evolution in multiple sclerosis patients initiating interferon-beta... by stuart Patient Expert

summary: Different coping strategies have been described in people dealing with stressful situations. Symptoms of anxiety and depression may occur in a high percentage of people recently diagnosed with MS, especially if they are about to start treatment. In this article the authors aimed to investigate whether the levels of anxiety and depression i ... Read on »

Extavia, an interferon beta-1b, was approved for use in patients with early and relapsing forms of... by stuart Patient Expert

By Eva von Schaper and Dermot DohertyMay 26 ( Bloomberg ) -- Novartis AG won European approval for a multiple sclerosis drug that's identical to Bayer AG's Betaseron, the German company's second best-selling medicine.Extavia, an interferon beta-1b, was approved for use in patients with early and relapsing forms of MS, Basel, Sw ... Read on »

Biogen Idec Announces First Patient Enrolled in the Global Phase III Study of PEGylated Interferon... by stuart Patient Expert

... the first patient in a Phase III, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of PEGylated interferon beta-1a (BIIB017) in patients with relapsing multiple sclerosis (RMS). The trial, called ADVANCE, will determine the efficacy of PEGylated interferon beta-1a in ... Read on »

The REGARD Study – A Head-to-Head Comparison of Rebif®® (glatiramer acetate) 44 mcg... by stuart Patient Expert

... were presented at the recent 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The REGARD study compared Rebif (interferon beta-1a) 44 mcg and Copaxone (glatiramer acetate) over 96 weeks in patients with relapsing-remitting MS. Principal investigator, Daniel Mikol, MD, PhD, from the Department ... Read on »

Long-term effect of early treatment with interferon beta-1b after a first clinical event... by stuart Patient Expert

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trialsummary: In relapsing-remitting MS, peop ... Read on »

A single-centre, randomized, double-blind, placebo-controlled study of interferon beta-1b on... by stuart Patient Expert

... a beneficial effect of immunomodulatory drugs shouldnot be ruled out in primary progressive multiple sclerosis.Our aim is to investigate the safety and efficacy of interferonbeta-1b in primary progressive multiple sclerosis. We conducteda double-blind, stratified, randomized, parallel group, phaseII pilot study where patients with primary progress ... Read on »

MS eJournal Club's webcast on interferon beta-1b versus 20 mg glatiramer acetate - Taking place on... by stuart Patient Expert

... px?id=5===========================Paul O’Connor, MD, and Michael Kaufman, MD, will discuss an article recently published inThe LancetNeurology, "250 µg or 500 µg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study."After the live discussion, join us for an i ... Read on »

New Interferon Formulations Promise to Eliminate Injections in Multiple Sclerosis Treatment by stuart Patient Expert

... c. and Aegis Therapeutics LLC today announced preclinical results from their joint collaboration aimed at developing non-injectable formulations of the beta-interferons. The beta interferons, beta-1a (tradename Rebif(R)), and beta 1b (tradenames Betaseron(R) and Betaferon(R)) are closely related injectable protein drugs in the interferon family th ... Read on »